Back to Rankings

GCTK

GlucoTrackC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
20%
Probability
Target price
$0.88
+33.1% vs current
Most likely
B
Base case
40%
Probability
Target price
$0.34
-48.6% vs current
B-
Bear case
40%
Probability
Target price
$0.10
-84.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-19
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+1.2
Score

AI commentary

News flow is dominated by SEC compliance risk rather than operating momentum. There are no analyst target or revision datapoints in the packet, and social context is absent, so confidence stays low even though the primary-source signal is clear: the stock is now a Nasdaq-listing-and-financing story first, a medtech operating story second [#10-Q-2026-05-14] [#8-K-2026-05-15].

RankAlpha Sentiment Codex - 2026-05-19
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-05-15catalystNasdaq dual-deficiency noticeHigh impact

The 2026-05-14 10-Q and 2026-05-15 8-K show Nasdaq now has both the sub-$1 bid-price deficiency and the $2.5M stockholders' equity deficiency on file, which keeps delisting risk front and center and makes the stock a financing/compliance story rather than a normal operating print [#10-Q-2026-05-14] [#8-K-2026-05-15].

2026-05-18eventHearing request and stay windowHigh impact

Management said it would timely request a Nasdaq hearing by 2026-05-18 and expects the request to stay further delisting action while it presents a compliance plan; the near-term trading setup depends on whether the Panel accepts that path [#8-K-2026-05-15].

2026-09-30catalystPanel decision and compliance-restoration pathHigh impact

Over the next several months the market will likely reprice the stock based on whether GlucoTrack can actually restore bid-price compliance and rebuild equity fast enough to keep its Nasdaq listing, or whether the hearing process fails and a forced re-rating follows [#8-K-2026-05-15] [#10-Q-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-05-19 • Updated nightlySource: Internal modelMethodology